Monte Rosa Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Monte Rosa Therapeutics, Inc. (GLUE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-72.70-135.35-108.50-73.96-35.88
Depreciation & Amortization8.126.223.752.130.54
Stock Based Compensation18.1316.6711.665.200.35
Change in Working Capital91.4062.29-2.136.294.26
Change in Accounts Receivable0.331.90-0.190.000.00
Change in Accounts Payable6.255.76-0.74-0.713.44
Change in Other Working Capital84.8114.814.810.960.82
Other Operating Activities-2.9523.064.810.967.68
Net Cash from Operating Activities42.00-43.80-92.47-59.36-23.05
Investing Activities
Capital Expenditures-3.9919.04-12.91-9.73-3.39
Purchases of Investments-230.36-103.15-384.420.000.00
Sales/Maturities of Investments189.90-57.52178.000.000.00
Net Cash from Investing Activities-44.4588.80-219.22-9.65-3.39
Financing Activities
Common Stock Issued0.942.6120.06237.750.00
Common Stock Repurchased-0.64-0.120.000.000.00
Other Financing Activities98.59-0.12-0.36-3.34-0.44
Net Cash from Financing Activities98.8927.4920.47377.5660.06
Summary
Net Change in Cash96.4472.49-291.22308.5533.62
Cash at Beginning of Period132.6860.19351.4142.860.00
Cash at End of Period229.12-120.3060.19351.410.00
Free Cash Flow38.01-62.78-105.38-69.10-26.44